Global circulating Tumor Cells Market: Snapshot

The global circulating tumor cells prognostic technologies market are rising in demand due to increasing demand for diagnostic technologies. This rise in demand for these technologies are primarily due to prevalence rate of cancer. Huge application scope of these technologies are dependent on safety of patients. Substantial Rise in therapeutic monitoring is rising the demand for the market. Increased death rates due to development of metastases and hematogenous dissemination of cancer is also boosting the need for detection of circulating tumor cells. Novel technologies for detection of circulating tumor cells are rising in demand due to many clinical trials including them as their secondary end points and in their translation research programs. The global market is expecting wider implementation possibilities of circulating tumor cells prognostic technologies in the coming years due to increasing rate of research and development activities conducted for developing personalized medicines.

According to a report by Transparency Market Research, the global circulating tumor cells prognostic technologies market is anticipated to rise at a tremendous CAGR of 26.30% during the forecast period of 2014 to 2020. The global market value is expected to attain a valuation of US$2.16 bn by the end of the forecast period.

Rise in Breast Cancer to Supplement Application of Technology with CAGR of 27.10% by 2020

The global circulating tumor cells prognostic technologies market have been segmented according to technology and applications. Technology segment is further sub segmented into tumor cell enrichment and tumor cell detection. The tumor cell detection segment is further bifurcated into molecular method and optical method. Among these, optical method segment is anticipated to rise at a rising CAGR of 27.30% during the forecast period of 2014 to 2020. The tumor cell enrichment is further sub segmented into immunomagnetic method and immunological method, centrifugation, and filtration. Among these sub segments, immunomagnetic method will account for the largest share in the tumor cell enrichment segment.

The global circulating tumor cells prognostic technologies by application is segmented into prostate cancer, breast cancer, colorectal cancer, pancreatic cancer, lung cancer, and ovarian cancer. Among these sub segments, prostate cancer is expected to rise at a significant CAGR of 25.20% during forecast period whereas, the breast cancer segment is anticipated to reach 27.10% CAGR by the end of 2020. Rise in breast cancer is accounting for a significant share in the market and is expected to rise in the coming years.

Increasing Prognostic Technologies to Boost North America Market

The global circulating tumor cells prognostic technologies market is spread across various regions such as North America, Asia pacific, Europe, and the rest of the world. Among these, North America is holding the largest shares in the market due to increased incidence and prevalence of cancer. The market in this region is also dominating the market due to increased adoption rate of advanced prognostic technologies. North America has disposable income that people are willing to spend on healthcare thus, it boosts the market in this region. Government’s extensive support for research and development in this region is supplementing the market growth of North America.

Similarly, Asia Pacific is also experiencing significant growth rate in the market. This region is experiencing steady growth in the market due to rise in various types of cancers among the people. The key players and government of various countries in this region is encouraging research and development activities to produce better technologies. Innovations have led to increased adoption rate of advanced therapeutic monitoring technologies in this region. Rise in population has resulted in rise of different types of cancer. Emerging economies in this region are showing potential rise in advancement and implication of the technologies.

Some of the key players operating in the circulating tumor cells prognostic technologies market are Epic Science, Silicon Biosystems, Vitatex, Veridex, and AVIVA Biosciences Corp.

This report provides the market analysis for various technologies and applications used for the enrichment and detection of circulating tumor cells (CTCs). The stakeholders of this report include companies and research institutes involved in the production of prognosis kits and research and development activities related to circulating tumor cells technologies as well as the new entrants who wish to enter this market.
 
The market overview section of the report analyzes the market dynamics and trends such as drivers, restraints and opportunities that would affect the current and future scenario of the CTC technologies market. Porter’s five forces analysis is included in this study to provide thorough analysis about the competitive status, and market attractiveness analysis has been added to describe the market outlook in different geographies. Event impact analysis is provided in this report for a brief understanding of the technological advancements that have taken place in the past and are planned for the future. Value chain analysis of the market is discussed to recognize value-creating activities from a number of processes, which can provide CTC technology a competitive advantage over other technologies.
 
Circulating tumor cells (CTCs) are specialized rare cells detached from primary tumors and disseminated in the vasculature system of the body, eventually causing metastasis. CTCs are composed of cells that act as seeds for successive development of additional metastatic tumors in essential distant organs, which is a cause of majority of cancer-related deaths. These CTCs are not easily detected, as these are present in less numbers in the blood stream. Tumors shed nearly 1 million circulating tumor cells (CTCs) per gram of tumor tissue. The global circulating tumor cells (CTCs) prognostic technologies market is segmented based on technologies and applications. Moreover, the technology market is further segmented into tumor cell enrichment and tumor cell detection. 
 
Based on tumor cell enrichment technologies, the report includes market analysis of filtration, centrifugation and immunological & immunomagnetic enrichment methods. Based on tumor cell detection technologies, the market is segmented into molecular methods and optical methods. Furthermore, based on the applications, the CTC prognostic technologies market is segmented into breast cancer, colorectal cancer, prostate cancer and others (lung, ovarian and pancreatic cancer). Market forecast for all these segments has been provided in the report for the period 2012 to 2020 in terms of USD million, along with CAGR for the forecast period 2014 to 2020, considering 2013 as the base year.
 
Geographically, the global CTCs prognostic technologies market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). North America is the leading market for CTCs prognostic technologies owing to the high adoption rate for advanced prognostic technologies as well as high prevalence and incidence rate of cancer. However, low commercial availability of these technologies and stringent regulatory approvals of these technologies are some of the factors that have led to the sluggish growth of this market. However, other regions such as Asia-Pacific is also expected to show a substantial growth rate owing to the increasing base of cancer patients coupled with high government support and growing adoption rate for advanced therapeutic monitoring technologies. The market revenue of CTC technologies for 2012 and 2020 and forecast from 2014 to 2020 in respective regions in terms of USD million and value percentage, respectively, is explained in this section of the report.
 
The report concludes with the profiles of key players in the CTC technologies market. Major companies profiled in this report include AdnaGen AG, Advanced Cell Diagnostics, Inc., AVIVA BioSciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc., Silicon Biosystems, S.p.A., Veridex, LLC, Vitatex, Inc. and others.
 
The global circulating tumor cells (CTCs) prognostic technologies market is segmented as follows:
  • Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Technology
    • Tumor Cell Enrichment
      • Filtration
      • Centrifugation
      • Immunological & Immunomagnetic Methods
    • Tumor Cell Detection
      • Molecular Methods
      • Optical Methods
  • Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Applications
    • Prostate Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Others (Lung, Ovarian and Pancreatic Cancer)
.